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Introduction
Myotonic dystrophy type 1 (DM1), or “Steinert’s 
disease”, is an inherited multisystemic disorder 
caused by an unstable expansion of cytosine – 
thymine – guanine (CTG) repeat in the non-translated 
region of the dystrophia myotonica-protein kinase 
gene (DMPK) (Huang & Kuo 2005; Jorde et al. 
2006; Finsterer et al. 2007); the mutation causes 
mis-splicing of mRNA species which can affect 
many cellular processes in different organs and 
tissues (Udd, 2012). Longer CTG repeat expansions 
are frequently associated with a more disabling 
phenotype but there is still not final agreement about 
this complex correlation (Udd & Krahe 2012). The 
most common clinical features of DM1 phenotype 
include progressive muscular weakness, myotonia, 
cardiac arrhythmias, respiratory failures, daytime 
sleepiness and cognitive disorders (Harper, 2001; 
van Engelen 2015).
Although fatigue is a major condition in many 
chronic and progressive physical illnesses, it is 
reported to be more common in DM1 than in 
other neuromuscular diseases (Laberge et al. 2009) 
and most patients complain muscle fatigue since 
the early stages of disease even in absence of a 
strong correlation with the objective motor disability 
(Kalkman et al. 2005). Fatigue can be defined as 
the inability to maintain the expected level of motor 
performance over time (Allen et al. 2008), but its 
pathophysiology remains unclear (Kalkmann et al. 
2005, Boerio et al. 2012).
Fatigue associated with motor performance has been 
considered to consist of two components: central and 
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A B S T R A C T
DM1 is an autosomal-dominant disorder characterized by muscle weakness, myotonia, and multisystemic 
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0.01, r-after= -0.534, p < 0.05), and to motor disability measured by MRC (r = -0.496, p < 0.05); moreover we 
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are discussed to define whether or not, based on clinical and laboratory grounds, such exercise training protocol 
may be suitable for proper management of DM1 patients; proper assessment of fatigue should be included in 
algorithms for data collection in DM1 patient registries.
Key words
Myotonic Dystrophy • Fatigue • Central • Peripheral • Exercise
44 S. BALDANZI ET AL. 
peripheral. Central fatigue is a progressive reduction 
in voluntary muscle activation during exercise, 
related to spinal or supraspinal factors (Gandevia, 
2001; Taylor and Gandevia, 2008), while peripheral 
fatigue results from an altered neuromuscular 
transmission or muscular dysfunction.
A study of isometric exercise using transcranial motor 
cortex stimulation by Taylor and co-workers (2006) 
provided evidence that central fatigue emanates upstream 
of the pre-motor cortex in the prefrontal areas of the brain 
associated with cognitive and behavioural function. 
Bray et al. (2012) suggested that in healthy subjects 
the decrease in maximal force production observed 
during repeated maximal voluntary contraction (MVC) 
can be caused by a central mechanism, specifically the 
expenditure of CNS resources.
These considerations suggest that further studies 
on parallel CNS and muscle involvement could be 
useful to define the fatigability in DM1 patients.
Muscle fatigue could be due to coupling excitement-
contraction, to lack of availability of substrates or 
blood flow and lack of adaptation of vasodilatation by 
nitric oxide (NO), and to the possible modifications 
of the intracellular environment and disruption of 
contractile apparatus (Heydemann et al. 2009).
Oxidative stress has been proposed to be one of 
the pathogenic factors of fatigue consequent to 
DM1 (Angelini and Tasca, 2012). Some studies 
linking nitric oxide species (NOS) and myotonic 
dystrophy suggests that although they are required 
for induction of dystrophia myotonica protein kinase 
(DMPK) expression during myogenesis, there is 
only a weak functional implication for such a 
generation and subsequent maintenance of DMPK 
expression (Carrasco et al. 2002).
Despite the fact that fatigue and exercise-induced fatigue 
are prominent in patients with DM1, limiting daily 
living activities and thereby affecting quality of life, this 
phenomenon remains poorly understood. Our aim has 
been then to get an overview of central and peripheral 
components of fatigue in a sample of patients meeting 
both genetic and clinical criteria for DM1, through a 
specifically designed multidimensional protocol.
Methods
Twenty-six patients with clinical and genetic 
diagnosis of DM1, according the International 
Consortium for myotonic dystrophies guidelines 
(Moxley et al. 2002), referred to Neurological 
Clinic of University of Pisa, were recruited: 17 
men, 9 women; age range 19-67 yrs; 41.6 ± 12.7 
years. The study was conducted according to the 
principles expressed in the Declaration of Helsinki 
and written information about the purpose of the 
study was provided to all the patients before giving 
their consent.
Patients affected by serious psychiatric comorbidities 
were excluded.
Clinical and demographic characteristics of the 
patient sample are shown in Table 1.
The experimental protocol was displayed into three 
examination sessions:
a) comprehensive clinical evaluation;
b) behavioural assessment of experienced 
fatigue through the administration of specific 
questionnaires and clinical scales;
c) intermittent handgrip exercise protocol.
a) Neurological examination included clinical history 
collection and evaluation of muscle involvement, 
scored by Medical Research Council scale (MRC, 
Medical Research Council, 1943). Motor impairment 
was then assessed through Muscular Impairment 
Rating Scale (MIRS, Mathieu et al. 2001).
All patients were sub-grouped on the basis of CTG 
expansion size (Table 1). A complete assessment of 
extra-muscular clinical features was also performed, 
including evaluation of cardiac, respiratory, gastro-
intestinal, ocular and endocrinological involvement.
b) Behavioural assessment.
The assessment of experienced fatigue was performed 
by a trained psychologist, blinded to clinical 
examinations, in a quiet and comfortable room.
FSS-Fatigue Severity Scale
Fatigue Severity Scale-FSS is one of the most 
common questionnaire used to assess the impact 
of fatigue on daily activities; it has showed good 
reliability in DM1 (Krupp 1989; Laberge 2005).
Individualized Neuromuscular Quality 
of Life, INQoL
In order to investigate the disease subjective 
experience, we adopted the Individualized 
Neuromuscular Quality of Life Questionnaire 
(INQoL, Sansone et al. 2010), a 10 items-structured 
interview, that captures patient’s physical and 
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psychosocial limitations related to the muscle 
disease. Single domain scores and a total score are 
calculated in term of percentage: a higher percentage 
is indicative of a greater impact of the disease on 
quality of life.
Cognitive assessment of attention abilities
Since motor performance also requires the expenditure 
of CNS processes, that tap into attentional resources, 
each participant underwent a cognitive assessment 
session focusing on attentional abilities, with the 
aim to identify patients affected by significant 
dysfunction likely to account for reduction in 
overall performance. A trained neuropsychologist 
administered the following protocol:
• trail Making Test (A and B tables, Reitan et al. 
1958);
• stroop test (Lezak et al. 2012);
• digit span (Spinnler e Tognoni 1987).
ESS-Epworth Sleepiness Scale
The Epworth Sleepiness Scale (ESS), was developed 
to measure the general level of sleepiness, 
conceptually defined as sleep propensity (Johns 
1991).Scores of 10 or higher are considered as 
indicative of excessive daytime sleepiness.
c) Intermittent handgrip exercise protocol.
A handgrip dynamometer (Multi-Myometer, MIE 
Medical research Ltd., Leeds, UK) was used to monitor 
and record muscle force generation (in Newtons: 
N) during maximal voluntary handgrip contractions 
(MVC). Drawing from procedures described by 
Søgaard et al. (2006), and in order to prevent hand 
myotonia, participants performed a pre-test warm-up 
phase consisting of some (4-5) series of intermittent 
hand contractions using a foam rubber ball. Then, at 
5-min intervals thereafter, participants completed a 
single MVC, each lasting 5-s in duration. The force 
produced during a 1-s window straddling the peak 
force value generated during each MVC squeeze was 
used for analyses. All contractions were performed 
while sitting at a table, with the forearm outstretched 
at 90° elbow flexion and parallel to the sagittal plane 
in a static, neutral posture (i.e., positioned halfway 
between pronation and supination) with the elbow 
and base of the hand situated on a forearm/hand 
tracing superimposed on the flat surface of the table. 
Participants were given verbal instructions to “squeeze 
the handles as hard as possible for 5 seconds” prior 
to each MVC and verbal encouragement to “squeeze 
hard, hard, hard”. The exercise was performed with 
the patient’s dominant arm (Figure 1).
In order to standardize force production across a 
broad range of raw force production values (i.e., 
some people had much higher force production than 
others), patients were asked to make 3 MVC, with 
5 minutes interval to recover and the mean MVC 
value was computed; recovery from warm-up was 
then carried out for 20 minutes.
Tab. 1. - Clinical and demographic characteristics of recruited DM1 patients.
Patients Enrolled (clinical study) 26
Muscular exercise protocol 20
Age Age range 19-67 yrs,
Sex 17 men, 9 women
[CTG]n E1 N=4 15.4%
[CTG]n E2 N=20 76.9%
[CTG]n E3 N=2 7.7%
BMI 24.9 ± 5.63 kg/m2
Time from disease onset 17.8 ± SD 12.7 years
Severity of muscular (MIRS) (MIRS)
involvement (MIRS)
MIRS=1 N=0
MIRS=2 N=12 46.1%
MIRS=3 N=10 38.5%
MIRS=4 N=4 15.4%
MIRS=5 N=0
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Blood sampling was performed before the beginning 
of the exercise protocol to determine baseline lactic 
acid (LA), creatine phosphokinase (CPK) and 
markers of oxidative stress (AOPP, FRAP, SH) 
levels.
The exercise protocol consisted of 3 trials of 
intermittent fatiguing contractions, lasting 1 minute 
each separated by 1 min of rest; the 3 trials 
were performed respectively at 20%-40%-60% of 
individual mean MVC. During exercise, a visual 
feedback helped the subjects to maintain a steady 
contraction and full attention.
Blood sampling was then performed to assess LA, CPK 
and markers of oxidative stress (AOPP, FRAP, SH) 
levels immediately after the end of the exercise protocol.
After 4’ at rest, residual MVC (MVC_60%) was 
determined through one single attempt of maximal 
strength lasting 5’.
Statistics
Statistical analyses were carried out using the 
Statistical Package for Social Science (SPSS), version 
21.0 and were performed by a medical statistician.
In order to investigate the relationship between 
central and peripheric measures of fatigue, we 
computed the bivariate correlation coefficients, 
Pearson’s coefficient for parametric variables and 
Spearman’s coefficient for non parametric variables. 
Variables were compared between groups using 
the Pearson chi-square for categorical variables, 
Student t test, the Mann-Whitney U test. The p value 
< 0.05 was considered statistically significant. All 
statistical tests were two tailed.
Results
Clinical assessment
All patients (N=26) were molecularly defined and 
grouped on the basis of CTG repeat classes (Table 
1). Mean time from disease onset was 17.8 ± SD 
12.7 years; only one patient had a congenital onset 
of DM1.
Muscular impairment was assessed by MRC 
(Medical Research Council) and categorized 
Muscular Impairment Rating Scale (MIRS).
[CTG]n expansion class was significantly associated 
to muscle impairment measured by MIRS (r = 
-0.439; p < 0.05) and by MRC (r = -0.439; p < 0.05); 
moreover MRC was negatively related to patients 
age (r = -0.425; p < 0.05), and positively to MVC_
baseline and MVC_60% (r = 0.640 and r = 0.584 
respectively, p<0,01).
Mean MRC score was 71.61± 7,82 DS (Table 1).
[CTG]n genetic expansion show significant 
correlations to motor disability assessed by MIRS 
(r = 0.640; p < 0.01) and by total MRC score (r = 
-0.536; p < 0.01).
Patients’ extramuscular involvement has been 
described in Table 2.
Fig. 1. - Study design diagram.
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Tab. 2. - Multisystemic features of recruited DM1 patients.
Cardiological 12 46.1%
Respiratory 11 42.3%
Ocular 7 26.9%
Endocrinological 9 34.6%
Gastrointestinal 12 46.1%
Swallowing 8 30.8%
included cardiac (n=12, 46.1%; 3 patients with pacemaker) and respiratory impairment (n=10, 38.5%; 8 patients using 
VMNI). Moreover 26.9% of patients had ocular impairment (mainly cataract); 34.6% had endocrine system impairment; 
46.1% had gastrointestinal symptoms (prevalentemente colelitiasi ed alternanza stipsi-diarrea) and 30.8% had troubles with 
swallowing. Only one patient presented with an obstructive sleep apnea syndrome. (conteggiato nel respiratorio).
Biochemical Parameters: lactic acid and 
markers of oxidative stress
Under basal conditions lactic acid levels in DM1 
patients resulted 12.665 mg/dl ± 6.001 (normal values 
4.5-19.8 mg/dl). At 60% of MVC lactic acid levels 
were 23.004 ± 8.443 mg/dl: an increase of 81,63% 
respect to baseline was observed (p<0,001), which 
indicates that patients reached the anaerobic threshold.
Baseline values of oxidative stress biomarkers have 
been compared with a healthy subjects control group 
of 15 subjects, matched for age and sex.
AOPP basal values resulted significantly higher in 
patients respect to healthy controls (patients: 375.95 
± 176.21 nmol/ml; HC: 163.59 ± 123.34 nmol/ml; 
p=0,0002); conversely no significant differences 
were found between and HC in FRAP and plasmatic 
thiols (FRAP in mmol/l, mean ± sd: 0.7403 ± 
0.1367; plasmatic thiols in µmol/l, mean ± sd: 
0.3827 ± 0.112) and HC (FRAP in mmol/l, mean ± 
sd: 0.801 ± 0.104; plasmatic thiols in µmol/l, mean ± 
sd: 0.432±0.303). At 60% of MVC oxidative stress 
biomarkers do not differ statistically from baseline.
Perceived fatigue assessment
Subjective perception of fatigue was assessed 
calculating FSS total score and single item score: 
mean total score (mean ± sd) was 4.8 ± 0.2, cut-off=4.6 
(Krupp et al. 1989), (Figure 2). Total FSS score (43.6 
± 12.4) is significantly associated to different clinical 
and physiological measures of fatigue. Single item 
analysis scores are shown in Figure 2. Statistical 
analysis revealed that total FSS score (mean ± sd) was 
43.6 ± 12.4 and resulted significantly associated to: 
total MRC (r = -0.496; p = 0.01); MVC_baseline (r = 
-0.583; p < 0.01); MVC_60% (r = -0.534; p < 0.05); 
mean patients age (r = 0.428; p < 0.05).
We found a strong tendency towards significance in 
the association between FSS total score and baseline 
lactic acid value (r = 0.378; p = 0.057).
Quality of life assessment
Figure 3 shows the altered domains of quality of 
life detected by INQoL interview in DM1 patients 
(higher percentages correspond to higher disease 
impact on patients’ QoL).
By considering the single INQoL Domain Scores, 
particularly item 1 and 4, we observed that the Fatigue 
domain (44.6%) has high impact as well as the 
Weakness domain (49.3%). Patients answers to item 
1 of the INQoL (“Do you have any muscle weakness 
due to your muscle condition?”) regarding subjective 
muscle weakness have been expressed on a 7-point 
Likert scale and correlate with [CTG]n (Spearman r 
= 0.459; p < 0.05) and with motor disability expressed 
by MIRS (Spearman r = 0.519; p < 0.01).
Patients answers to item 4 of the INQoL (“Do 
you feel tired/ fatigued as a result of your muscle 
condition?”) do not show significant associations to 
any of the other variables.
Attentional resources
Cognitive assessment revealed that 46.2% of patients 
presents impaired attentional abilities while 50% 
shows normal attentional functioning; one patient 
was not compliant to test administration (Figure 4).
Daytime sleepiness evaluation
Mean total ESS score in our sample was (mean ± 
sd) 7.9 ± 3.4; only 6 patients (23.1%) reached the 
cut-off score for daytime sleepiness diagnosis; ESS 
total and single item scores did not correlate to any 
other clinical parameter (Figure 5).
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Muscular strength assessment through 
“hand-grip” exercise protocol
Among the recruited patients, the “hand-grip” 
exercise protocol was performed by 20 subjects; 6 
patients were not compliant to complete the exercise 
protocol.
The MVC was measured at baseline and at 
60% of individual mean MVC in order to test 
response to exercise: mean (±sd) MVC_baseline 
was 135.4 ± 101.7 and MVC_60% was 120.9 ± 
100.9; after the exercise there was a statistically 
significant decrease (MVC_baseline – MVC_60%) 
of maximum voluntary contraction (p<0,05) showing 
no statistically significant correlations with other 
variables investigated, except for age (r = -0.439; p < 
0.05), (Figure 6).
Discussion
Fatigue in DM1 is reported to be more common 
than in other neuromuscular diseases, even in 
absence of a clear association with the objective 
motor disability (Laberge et al. 2009). Fatigue 
substantially contributes to decrements in quality of 
Fig. 2. - Central dimensions of fatigue in DM1 patients assessed by Fatigue Severity Scale (FSS) item analysis; FSS 
mean total score (mean ± sd) 4.8 ± 0.2.
Fig. 3. - Quality of life assessment through INQoL interview of recruited DM1 patients, analyzing the impact of each 
symptom on various domains of everyday life; mean total INQoL score= 19,1%.
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life (Hermans et al. 2013, Ørngreen et al. 2005) but 
our understanding of the interaction between central 
and peripheral components is still limited and 
specific clinical rating tools have yet to be designed.
Muscle fatigue is a multifactorial process and 
different neurobiological mechanisms could be 
involved in its pathogenesis: previous works have 
indicated alterations of sarcolemmal excitability, 
electro-mechanical coupling, availability of energy 
substrates, blood flow and adaptation exercise with 
vasodilation induced by nitric oxide (NO), as well as 
any modifications intracellular environment altering 
the contractile apparatus and oxidative stress as 
interplaying factors (Angelini & Tasca 2012; Montes 
et al. 2011).
In order to address this issue we recruited 26 
adult-onset DM1 patients able to perform a 
multidimensional evaluation protocol specifically 
designed to evaluate “experienced” and 
“physiological” components of fatigue; the present 
study has taken to a preliminary definition of a 
clinical protocol for the characterization of both 
fatigue components in DM1 patients.
We defined a simple handgrip exercise protocol 
consisted of intermittent fatiguing contractions in 
order to evaluate the muscle response; this kind of 
exercise is mainly aerobic at the beginning of the 
test and becomes gradually anaerobic as the effort 
grows, due to progressive recruitment of rapid motor 
units (Milner-Brown et al. 1973).
This protocol showed to be easily deployable in 
clinical settings and it resulted reliable in assessing 
the ongoing muscle fatigue process (Figure 6), as 
documented by the significant decrease in MCV 
at the end of the exercise. All patients reached the 
anaerobic threshold as showed by the increase in 
muscle lactic acid after the exercise: at 60% MVC 
the increase was about 81.6% respect to baseline.
Our protocol also includes the assay of peripheral 
blood oxidative stress parameters at baseline and 
during exercise but it fails to detect changes in 
Fig. 4. - Percentages of DM1 patients affected by attentional dysfunction in the sample (N=13 normal abilities; N=12 
impaired abilities; N=1 uncompliant).
Fig. 5. - Prevalence of daytime sleepiness assessed by 
ESS scores.
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oxidative balance. The abnormal CTG repetition, 
responsible for an altered DMPK function in 
DM1, leads to a compromised myofiber metabolic 
homeostasis, thus increasing the susceptibility of 
cells to oxidative stress, through the activation 
of different pathways of signal transduction, as 
postulated by several evidences in literature (Usuki 
et al. 2000; Pantic et al. 2013). Notably, among the 
pathophysiological hypotheses of muscle fatigue, 
a huge amount of data seem to suggest oxidative 
stress as one of the main mechanisms involved in the 
genesis of muscle fatigue (Reid, 2008).
The lack of statistically significant differences 
between the levels of non-enzymatic antioxidants 
of patients compared to controls in our study may 
depend upon an excessive production of ROS in 
DM1 patients, resulting in increase of oxidative 
damage (documented by higher AOPP baseline 
levels patients compared to healthy controls), that 
is likely to be counteracted thus by compensatory 
mechanisms increasing the antioxidant defense.
Oxidative stress parameters do not show significant 
changes at 60% MVC compared to baseline, 
consistently with the fact that the length of exercise 
protocol could not be sufficient to account for the 
activation of the biochemical pathway that leads to 
protein damage by ROS, as well as an improvement 
in the antioxidant defence mechanisms. Moreover 
in basal conditions muscular exercise naturally 
determines an immediate increase in ROS production 
with an increase in antioxidant defences too. We 
assume that a longer kinetic could be necessary 
to have appreciable changes in oxidative stress 
biomarkers that should be reassessed at later stages 
after the end of the exercise (2-6-9-24 hours). 
Even if only few studies addressed this topic in 
literature up to now, it is interesting to note that 
previous works adopting an electrophysiological 
approach, found that a submaximal fatiguing motor 
task was not able to further affect the cortical and 
neuromuscular properties that were already altered 
at baseline in DM1 patients (Boerio et al. 2012); this 
finding is in line with our results, and in accordance 
with a further study that has showed smaller changes 
in peripheral characteristics of fatigue in patients 
with DM1 compared to healthy subjects (Schillings 
et al. 2007). We can argue that adaptation of cortical 
and neuromuscular properties to baseline alteration 
may prevent patients from an enhanced fatigue after 
an exercise performed at a given percentage of MVC 
compared to controls.
Fatigue has been also been also evaluated from 
patients’ subjective perspective and resulted 
associated with clinical parameters related to the 
underlying disease.
In particular, we observed an association between 
the degree of motor disability, assessed by MRC, 
and the total FSS score, indicating that patients 
Fig. 6. - Changes in muscular strenght after 60% effort. MVC= maximum voluntary contraction. Mean values 
(Newton, N): MVC baseline =135.4 ± 101.7; MVC 60% = 120.9 ± 100.9.
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with greater motor impairment also perceive greater 
fatigue. To this regard subjective experience of 
fatigue is also negatively associated to MVC, (both 
baseline and 60%), and positively to baseline lactate.
By administering INQoL questionnaire we assessed 
the impact of fatigue and muscular weakness 
on DM1 patinents’ QoL. According to previous 
observations (Baldanzi et al. 2016, Peric et al. 
2013, Meola and Sansone 2007), also in the present 
analysis INQoL total score revealed a mild impact 
of disease disability in DM1 patients. Statistical 
analysis showed an interesting association between 
subjective muscular weakness (item1), [CTG]
n expansion and motor disability (MIRS). None 
of the other patient reported measures correlates 
with physiological parameters of muscle fatigue, 
indicating that probably this clinical scale has as the 
primary focus to detect specific data on the daily life 
of patients.
In our sample the statistical analysis of correlation 
between daytime sleepiness, measured by ESS, and 
fatigue, measured by FSS, was not significant, despite 
the fact that 23% of patients report a moderate degree 
of daytime sleepiness (Figure 5). We may suggest 
that attention disorders, detected in about half of the 
recruited patients, and low disease awareness (Baldanzi 
et al. 2016), interfere with patients’ reliability to 
answer to the self-administered and to properly 
quantify the phenomenon of daytime sleepiness. In 
addition, muscle fatigue and daytime sleepiness show 
an a partially overlapping presentation (Hermans et 
al. 2013) that raise the need for validated and shared 
methodology to discriminate them.
It would be important to extend our study to a wider 
patients series to further investigate the relationship 
between functional assessment of the symptom 
“fatigue” and objective assessment by means of 
muscle exercise testing protocols. Moreover, the 
protocol has to be refined for a deeper understanding 
of the contribution of DM1-related brain dysfunction 
to motor performance: since a complete analysis of 
this phenomenon requires a combination of mental 
and physical demands, we should argue that a 
detailed evaluation of mood fluctuations could 
have been a helpful contribution to our study; 
future studies could aim to estimate to what extent 
cognitive and motor demands can interact with 
mood state, particularly considering the frequent 
occurrence of apathy in DM1 patients’ samples.
The utility of a “Fatigue protocol” evaluating central 
as well as peripheral dimensions allows us to assume 
possible applications in the clinical evaluation 
of muscle fatigue in myotonic dystrophy, in the 
implementation of case report forms for disease 
registries, and as a reference for the evaluation of 
disease staging and trial readiness.
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